The JAFRAL Phage Summit 2026 has officially unveiled its first event brochure, offering an early look at one of the most anticipated international meetings focused on phage therapy and antimicrobial resistance (AMR).
Scheduled to take place from 19–21 May 2026 in Ljubljana, Slovenia, the summit will bring together a global community of pharma and biotech innovators, clinicians, pharmacists, regulators, researchers, and industry leaders committed to advancing bacteriophage-based solutions for modern medicine.
Advancing Phage Therapy in the Era of Antimicrobial Resistance
As antimicrobial resistance continues to pose a growing global health threat, phage therapy is increasingly recognised as a promising complementary and alternative approach to traditional antibiotics. The JAFRAL Phage Summit 2026 aims to serve as a collaborative platform where scientific innovation, clinical practice, regulation, and industry development converge.
The newly released brochure outlines JAFRAL’s vision to translate phage therapy from research into real-world patient solutions, addressing both therapeutic development and implementation challenges.
What the Brochure Reveals
The brochure provides a first glimpse into what participants can expect from the three-day summit, including:
- Key scientific and clinical themes shaping the future of phage therapy
- The target audience, spanning academia, healthcare, industry, and policy
- Venue details at the historic Grand Hotel Union, located in the heart of Ljubljana
- Registration categories and pricing information
More information on confirmed speakers, session topics, and the detailed scientific programme is expected to be released in the coming weeks.
Hosting the summit in Slovenia’s Ljubljana reflects JAFRAL’s commitment to fostering international collaboration in an accessible, culturally rich European setting, marking it as an ideal location for dialogue at the intersection of science, policy, and clinical application.
About JAFRAL
JAFRAL is a biotechnology company specialising in the development and manufacturing of phage-based solutions for therapeutic and applied use. The company is recognised for its expertise in phage production, characterisation, and quality control, supporting the growing global effort to translate phage therapy from research into real-world clinical and industrial applications.
JAFRAL works at the intersection of phage therapy, antimicrobial resistance (AMR), and advanced biomanufacturing, providing services and partnerships that help accelerate the development of phage-based therapeutics. Its capabilities span phage isolation, optimisation, scale-up manufacturing, and analytical support, positioning the company as a key enabler within the international phage ecosystem.
Check more details here and don’t forget to use our code PHAGEBLOG5 for 5% discount on registration fees.
